{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:45:51Z","timestamp":1791294351956,"version":"4.1.0"},"reference-count":180,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T00:00:00Z","timestamp":1450656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institute for Health Research","doi-asserted-by":"crossref","award":["ISO-102447"],"award-info":[{"award-number":["ISO-102447"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Grifols"},{"name":"H\u00e9ma-Qu\u00e9bec Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00401-015-1518-9","type":"journal-article","created":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T04:07:12Z","timestamp":1450670832000},"page":"481-504","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Immunotherapies in Alzheimer\u2019s disease: Too much, too little, too late or off-target?"],"prefix":"10.1007","volume":"131","author":[{"given":"Isabelle","family":"St-Amour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cicchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Calon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,21]]},"reference":[{"issue":"216\u201325","key":"1518_CR1","first-page":"e1","volume":"11","author":"ADAPT-FS research group","year":"2015","unstructured":"ADAPT-FS research group (2015) Follow-up evaluation of cognitive function in the randomized Alzheimer\u2019s disease anti-inflammatory prevention trial and its follow-up study. Alzheimers Dement 11(216\u201325):e1","journal-title":"Alzheimers Dement"},{"key":"1518_CR2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cyto.2008.08.013","volume":"44","author":"G Ait-ghezala","year":"2008","unstructured":"Ait-ghezala G, Abdullah L, Volmar C-H, Paris D, Luis CA, Quadros A, Mouzon B, Mullan MA, Keegan AP, Parrish J, Crawford FC, Mathura VS, Mullan MJ (2008) Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer\u2019s disease. Cytokine 44:283\u2013287","journal-title":"Cytokine"},{"key":"1518_CR3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ca.980080612","volume":"8","author":"A Alzheimer","year":"1995","unstructured":"Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR (1995) An English translation of Alzheimer\u2019s 1907 paper, \u201cUber eine eigenartige Erkankung der Hirnrinde\u201d. Clin Anat 8:429\u2013431","journal-title":"Clin Anat"},{"issue":"2","key":"1518_CR4","first-page":"1","volume":"2012","author":"A Association","year":"2012","unstructured":"Association A (2012) Alzheimer\u2019s disease facts and figures. Alzheimers Dement 2012(2):1\u201372","journal-title":"Alzheimers Dement"},{"key":"1518_CR5","doi-asserted-by":"crossref","unstructured":"Anders HJ, Baumann M, Tripepi G, Mallamaci F (2015) Immunity in arterial hypertension: Associations or causalities? Nephrol Dial Transplant 11 Mar 2015. pii: gfv057 [Epub ahead of print]","DOI":"10.1093\/ndt\/gfv057"},{"key":"1518_CR6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/2047-9158-3-25","volume":"3","author":"KM Anderson","year":"2014","unstructured":"Anderson KM, Olson KE, Estes KA, Flanagan K, Gendelman HE, Mosley RL (2014) Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders. Transl Neurodegener 3:25","journal-title":"Transl Neurodegener"},{"key":"1518_CR7","author":"H Arai","year":"2015","unstructured":"Arai H, Umemura K, Ichimiya Y, Iseki E, Eto K, Miyakawa K, Kirino E, Shibata N, Baba H, Tsuchiwata S (2015) Safety and pharmacokinetics of bapineuzumab in a single ascending-dose study in Japanese patients with mild to moderate Alzheimer\u2019s disease. Geriatr Gerontol Int. doi: 10.1111\/ggi.12516","journal-title":"Geriatr Gerontol Int"},{"key":"1518_CR8","doi-asserted-by":"crossref","first-page":"9115","DOI":"10.1523\/JNEUROSCI.2361-07.2007","volume":"27","author":"AA Asuni","year":"2007","unstructured":"Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27:9115\u20139129","journal-title":"J Neurosci"},{"key":"1518_CR9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2990.2010.01137.x","volume":"37","author":"J Attems","year":"2011","unstructured":"Attems J, Jellinger K, Thal DR, Van Nostrand W (2011) Review: sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 37:75\u201393","journal-title":"Neuropathol Appl Neurobiol"},{"key":"1518_CR10","doi-asserted-by":"crossref","first-page":"84ra43","DOI":"10.1126\/scitranslmed.3002254","volume":"3","author":"JK Atwal","year":"2011","unstructured":"Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, Heise CE, Hoyte K, Luk W, Lu Y, Peng K, Wu P, Rouge L, Zhang Y, Lazarus RA, Scearce-Levie K, Wang W, Wu Y, Tessier-Lavigne M, Watts RJ (2011) A therapeutic antibody targeting BACE1 inhibits amyloid-{beta} production in vivo. Sci Transl Med 3:84ra43","journal-title":"Sci Transl Med"},{"key":"1518_CR11","doi-asserted-by":"crossref","first-page":"7613","DOI":"10.4049\/jimmunol.0803366","volume":"182","author":"P Bach","year":"2009","unstructured":"Bach P, Tsch\u00e4pe J-A, Kopietz F, Braun G, Baade JK, Wiederhold K-H, Staufenbiel M, Prinz M, Deller T, Kalinke U, Buchholz CJ, M\u00fcller UC (2009) Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice. J Immunol 182:7613\u20137624","journal-title":"J Immunol"},{"key":"1518_CR12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1517\/17460441.2012.666234","volume":"7","author":"KR Bales","year":"2012","unstructured":"Bales KR (2012) The value and limitations of transgenic mouse models used in drug discovery for Alzheimer\u2019s disease: an update. Expert Opin Drug Discov 7:281\u2013297","journal-title":"Expert Opin Drug Discov"},{"key":"1518_CR13","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00018-007-7081-3","volume":"64","author":"F Bartolome","year":"2007","unstructured":"Bartolome F, de Las Cuevas N, Munoz U, Bermejo F, Martin-Requero A (2007) Impaired apoptosis in lymphoblasts from Alzheimer\u2019s disease patients: cross-talk of Ca2+\/calmodulin and ERK1\/2 signaling pathways. Cell Mol Life Sci 64:1437\u20131448","journal-title":"Cell Mol Life Sci"},{"key":"1518_CR14","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC (2012) Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med 367:795\u2013804","journal-title":"N Engl J Med"},{"key":"1518_CR15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/01.WNL.0000148604.77591.67","volume":"64","author":"AJ Bayer","year":"2005","unstructured":"Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S (2005) Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64:94\u2013101","journal-title":"Neurology"},{"key":"1518_CR16","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.neuropharm.2009.01.006","volume":"56","author":"F Bourasset","year":"2009","unstructured":"Bourasset F, Ouellet M, Tremblay C, Julien C, Do TM, Oddo S, Laferla F, Calon F (2009) Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer\u2019s disease. Neuropharmacology 56:808\u2013813","journal-title":"Neuropharmacology"},{"key":"1518_CR17","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jalz.2010.12.014","volume":"7","author":"JC Breitner","year":"2011","unstructured":"Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN, R. G. ADAPT (2011) Extended results of the Alzheimer\u2019s disease anti-inflammatory prevention trial. Alzheimers Dement 7:402\u2013411","journal-title":"Alzheimers Dement"},{"key":"1518_CR18","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1530\/eje.0.1480535","volume":"148","author":"JM Bruun","year":"2003","unstructured":"Bruun JM, Verdich C, Toubro S, Astrup A, Richelsen B (2003) Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-alpha. Effect of weight loss in obese men. Eur J Endocrinol 148:535\u2013542","journal-title":"Eur J Endocrinol"},{"key":"1518_CR19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neulet.2008.10.091","volume":"450","author":"P Buchhave","year":"2009","unstructured":"Buchhave P, Janciauskiene S, Zetterberg H, Blennow K, Minthon L, Hansson O (2009) Elevated plasma levels of soluble CD40 in incipient Alzheimer\u2019s disease. Neurosci Lett 450:56\u201359","journal-title":"Neurosci Lett"},{"key":"1518_CR20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/WNF.0b013e318279bcfa","volume":"36","author":"AH Burstein","year":"2013","unstructured":"Burstein AH, Zhao Q, Ross J, Styren S, Landen JW, Ma WW, McCush F, Alvey C, Kupiec JW, Bednar MM (2013) Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease. Clin Neuropharmacol 36:8\u201313","journal-title":"Clin Neuropharmacol"},{"key":"1518_CR21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1755-5949.2011.00245.x","volume":"18","author":"J Butchart","year":"2012","unstructured":"Butchart J, Holmes C (2012) Systemic and central immunity in Alzheimer\u2019s disease: therapeutic implications. CNS Neurosci Ther 18:64\u201376","journal-title":"CNS Neurosci Ther"},{"key":"1518_CR22","doi-asserted-by":"crossref","first-page":"9096","DOI":"10.1523\/JNEUROSCI.1697-05.2005","volume":"25","author":"M Buttini","year":"2005","unstructured":"Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, Khan K, Seubert P, Freedman S, Schenk D, Games D (2005) Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer\u2019s disease. J Neurosci 25:9096\u20139101","journal-title":"J Neurosci"},{"key":"1518_CR23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0197-4580(01)00246-9","volume":"23","author":"NY Calingasan","year":"2002","unstructured":"Calingasan NY, Erdely HA, Altar CA (2002) Identification of CD40 ligand in Alzheimer\u2019s disease and in animal models of Alzheimer\u2019s disease and brain injury. Neurobiol Aging 23:31\u201339","journal-title":"Neurobiol Aging"},{"key":"1518_CR24","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/156720511796391881","volume":"8","author":"F Calon","year":"2011","unstructured":"Calon F (2011) Omega-3 polyunsaturated fatty acids in Alzheimer\u2019s disease: key questions and partial answers. Curr Alzheimer Res 8:470\u2013478","journal-title":"Curr Alzheimer Res"},{"key":"1518_CR25","doi-asserted-by":"crossref","first-page":"a018788","DOI":"10.1101\/cshperspect.a018788","volume":"7","author":"D Cantrell","year":"2015","unstructured":"Cantrell D (2015) Signaling in lymphocyte activation. Cold Spring Harb Perspect Biol 7:a018788","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1518_CR26","doi-asserted-by":"crossref","first-page":"27876","DOI":"10.1074\/jbc.M112.377549","volume":"287","author":"JG Cash","year":"2012","unstructured":"Cash JG, Kuhel DG, Basford JE, Jaeschke A, Chatterjee TK, Weintraub NL, Hui DY (2012) Apolipoprotein E4 impairs macrophage efferocytosis and potentiates apoptosis by accelerating endoplasmic reticulum stress. J Biol Chem 287:27876\u201327884","journal-title":"J Biol Chem"},{"key":"1518_CR27","doi-asserted-by":"crossref","first-page":"e18296","DOI":"10.1371\/journal.pone.0018296","volume":"6","author":"S Cattepoel","year":"2011","unstructured":"Cattepoel S, Hanenberg M, Kulic L, Nitsch RM (2011) Chronic intranasal treatment with an anti-Abeta(30\u201342) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer\u2019s disease. PLoS ONE 6:e18296","journal-title":"PLoS ONE"},{"key":"1518_CR28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/ni1551","volume":"9","author":"R Cayrol","year":"2008","unstructured":"Cayrol R, Wosik K, Berard JL, Dodelet-Devillers A, Ifergan I, Kebir H, Haqqani AS, Kreymborg K, Krug S, Moumdjian R, Bouthillier A, Becher B, Arbour N, David S, Stanimirovic D, Prat A (2008) Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol 9:137\u2013145","journal-title":"Nat Immunol"},{"key":"1518_CR29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2174\/187152710791011991","volume":"9","author":"GM Cole","year":"2010","unstructured":"Cole GM, Frautschy SA (2010) Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer\u2019s disease. CNS Neurol Disord: Drug Targets 9:140\u2013148","journal-title":"CNS Neurol Disord: Drug Targets"},{"key":"1518_CR30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1196\/annals.1332.005","volume":"1035","author":"GM Cole","year":"2004","unstructured":"Cole GM, Morihara T, Lim GP, Yang F, Begum A, Frautschy SA (2004) NSAID and antioxidant prevention of Alzheimer\u2019s disease: lessons from in vitro and animal models. Ann N Y Acad Sci 1035:68\u201384","journal-title":"Ann N Y Acad Sci"},{"key":"1518_CR31","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2174\/1567205011666140812114037","volume":"11","author":"SE Counts","year":"2014","unstructured":"Counts SE, Perez SE, He B, Mufson EJ (2014) Intravenous immunoglobulin reduces tau pathology and preserves neuroplastic gene expression in the 3xTg mouse model of Alzheimer\u2019s disease. Curr Alzheimer Res 11:655\u2013663","journal-title":"Curr Alzheimer Res"},{"key":"1518_CR32","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1523\/JNEUROSCI.4672-12.2013","volume":"33","author":"H Davtyan","year":"2013","unstructured":"Davtyan H, Ghochikyan A, Petrushina I, Hovakimyan A, Davtyan A, Poghosyan A, Marleau AM, Movsesyan N, Kiyatkin A, Rasool S, Larsen AK, Madsen PJ, Wegener KM, Ditlevsen DK, Cribbs DH, Pedersen LO, Agadjanyan MG (2013) Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer\u2019s disease: prelude to a clinical trial. J Neurosci 33:4923\u20134934","journal-title":"J Neurosci"},{"key":"1518_CR33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev-pharmtox-010814-124309","volume":"55","author":"B Strooper De","year":"2015","unstructured":"De Strooper B, Chavez Gutierrez L (2015) Learning by failing: ideas and concepts to tackle gamma-secretases in Alzheimer\u2019s disease and beyond. Annu Rev Pharmacol Toxicol 55:419\u2013437","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1518_CR34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1084\/jem.20091419","volume":"207","author":"NC Derecki","year":"2010","unstructured":"Derecki NC, Cardani AN, Yang CH, Quinnies KM, Crihfield A, Lynch KR, Kipnis J (2010) Regulation of learning and memory by meningeal immunity: a key role for IL-4. J Exp Med 207:1067\u20131080","journal-title":"J Exp Med"},{"key":"1518_CR35","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.neurobiolaging.2006.10.019","volume":"29","author":"G Desideri","year":"2008","unstructured":"Desideri G, Cipollone F, Necozione S, Marini C, Lechiara MC, Taglieri G, Zuliani G, Fellin R, Mezzetti A, di Orio F, Ferri C (2008) Enhanced soluble CD40 ligand and Alzheimer\u2019s disease: evidence of a possible pathogenetic role. Neurobiol Aging 29:348\u2013356","journal-title":"Neurobiol Aging"},{"key":"1518_CR36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1474-4422(13)70014-0","volume":"12","author":"R Dodel","year":"2013","unstructured":"Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Forster S, Winter Y, Bach JP, Popp J, Alferink J, Wiltfang J, Buerger K, Otto M, Antuono P, Jacoby M, Richter R, Stevens J, Melamed I, Goldstein J, Haag S, Wietek S, Farlow M, Jessen F (2013) Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer\u2019s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 12:233\u2013243","journal-title":"Lancet Neurol"},{"key":"1518_CR37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1742-2094-11-48","volume":"11","author":"D Doens","year":"2014","unstructured":"Doens D, Fernandez PL (2014) Microglia receptors and their implications in the response to amyloid beta for Alzheimer\u2019s disease pathogenesis. J Neuroinflammation 11:48","journal-title":"J Neuroinflammation"},{"key":"1518_CR38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neurobiolaging.2007.07.015","volume":"30","author":"AJ Farrall","year":"2009","unstructured":"Farrall AJ, Wardlaw JM (2009) Blood\u2013brain barrier: ageing and microvascular disease\u2013systematic review and meta-analysis. Neurobiol Aging 30:337\u2013352","journal-title":"Neurobiol Aging"},{"key":"1518_CR39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1750-3639.2004.tb00493.x","volume":"14","author":"I Ferrer","year":"2004","unstructured":"Ferrer I, Rovira MB, Guerra MLS, Rey MJ, Costa-Jussa F (2004) Neuropathology and pathogenesis of encephalitis following amyloid beta immunization in Alzheimer\u2019s disease. Brain Pathol 14:11\u201320","journal-title":"Brain Pathol"},{"key":"1518_CR40","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF03401753","volume":"4","author":"M Fiala","year":"1998","unstructured":"Fiala M, Zhang L, Gan X, Sherry B, Taub D, Graves MC, Hama S, Way D, Weinand M, Witte M, Lorton D, Kuo YM, Roher AE (1998) Amyloid-beta induces chemokine secretion and monocyte migration across a human blood\u2013brain barrier model. Mol Med 4:480\u2013489","journal-title":"Mol Med"},{"key":"1518_CR41","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jalz.2015.05.010","volume":"11","author":"EE Franklin","year":"2015","unstructured":"Franklin EE, Perrin RJ, Vincent B, Baxter M, Morris JC, Cairns NJ (2015) Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer\u2019s disease neuroimaging initiative 2 participants. Alzheimers Dement 11:815\u2013822","journal-title":"Alzheimers Dement"},{"key":"1518_CR42","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jaci.2014.01.032","volume":"134","author":"SC Gale","year":"2014","unstructured":"Gale SC, Gao L, Mikacenic C, Coyle SM, Rafaels N, Murray Dudenkov T, Madenspacher JH, Draper DW, Ge W, Aloor JJ, Azzam KM, Lai L, Blackshear PJ, Calvano SE, Barnes KC, Lowry SF, Corbett S, Wurfel MM, Fessler MB (2014) APOepsilon4 is associated with enhanced in vivo innate immune responses in human subjects. J Allergy Clin Immunol 134:127\u2013134","journal-title":"J Allergy Clin Immunol"},{"key":"1518_CR43","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nri3433","volume":"13","author":"H Geiger","year":"2013","unstructured":"Geiger H, de Haan G, Florian MC (2013) The ageing haematopoietic stem cell compartment. Nat Rev Immunol 13:376\u2013389","journal-title":"Nat Rev Immunol"},{"key":"1518_CR44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/187152710791012099","volume":"9","author":"B Giunta","year":"2010","unstructured":"Giunta B, Rezai-Zadeh K, Tan J (2010) Impact of the CD40-CD40L dyad in Alzheimer\u2019s disease. CNS Neurol Disord: Drug Targets 9:149\u2013155","journal-title":"CNS Neurol Disord: Drug Targets"},{"key":"1518_CR45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/WAD.0b013e3181611024","volume":"22","author":"T Gomez-Isla","year":"2008","unstructured":"Gomez-Isla T, Blesa R, Boada M, Clarimon J, Del Ser T, Domenech G, Ferro JM, Gomez-Anson B, Manubens JM, Martinez-Lage JM, Munoz D, Pena-Casanova J, Torres F (2008) A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord 22:21\u201329","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1518_CR46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13195-015-0126-1","volume":"7","author":"D Gomez-Nicola","year":"2015","unstructured":"Gomez-Nicola D, Boche D (2015) Post-mortem analysis of neuroinflammatory changes in human Alzheimer\u2019s disease. Alzheimers Res Ther 7:42","journal-title":"Alzheimers Res Ther"},{"key":"1518_CR47","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.molimm.2013.06.016","volume":"56","author":"B Gong","year":"2013","unstructured":"Gong B, Pan Y, Zhao W, Knable L, Vempati P, Begum S, Ho L, Wang J, Yemul S, Barnum S, Bilski A, Gong BY, Pasinetti GM (2013) IVIG immunotherapy protects against synaptic dysfunction in Alzheimer\u2019s disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C\/EBP signaling pathway. Mol Immunol 56:619\u2013629","journal-title":"Mol Immunol"},{"key":"1518_CR48","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1016\/j.neurobiolaging.2012.01.015","volume":"33","author":"S Guadagna","year":"2012","unstructured":"Guadagna S, Esiri MM, Williams RJ, Francis PT (2012) Tau phosphorylation in human brain: relationship to behavioral disturbance in dementia. Neurobiol Aging 33:2798\u20132806","journal-title":"Neurobiol Aging"},{"key":"1518_CR49","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/WNR.0b013e328358a044","volume":"23","author":"X Guan","year":"2012","unstructured":"Guan X, Zou J, Gu H, Yao Z (2012) Short amyloid-beta immunogens with spacer-enhanced immunogenicity without junctional epitopes for Alzheimer\u2019s disease immunotherapy. NeuroReport 23:879\u2013884","journal-title":"NeuroReport"},{"key":"1518_CR50","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J (2013) TREM2 variants in Alzheimer\u2019s disease. N Engl J Med 368:117\u2013127","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1518_CR51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2249.2009.04024.x","volume":"158","author":"H-P Hartung","year":"2009","unstructured":"Hartung H-P, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S (2009) Clinical applications of intravenous immunoglobulins (IVIg)\u2013beyond immunodeficiencies and neurology. Clin Exp Immunol 158(Suppl 1):23\u201333","journal-title":"Clin Exp Immunol"},{"key":"1518_CR52","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP (2015) Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 14:388\u2013405","journal-title":"Lancet Neurol"},{"key":"1518_CR53","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrn3880","volume":"16","author":"FL Heppner","year":"2015","unstructured":"Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16:358\u2013372","journal-title":"Nat Rev Neurosci"},{"key":"1518_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jnc.12845","volume":"132","author":"A Herrmann","year":"2015","unstructured":"Herrmann A, Spires-Jones T (2015) Clearing the way for tau immunotherapy in Alzheimer\u2019s disease. J Neurochem 132:1\u20134","journal-title":"J Neurochem"},{"key":"1518_CR55","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/(SICI)1097-4547(19990801)57:3<295::AID-JNR1>3.0.CO;2-0","volume":"57","author":"L Ho","year":"1999","unstructured":"Ho L, Pieroni C, Winger D, Purohit DP, Aisen PS, Pasinetti GM (1999) Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer\u2019s disease. J Neurosci Res 57:295\u2013303","journal-title":"J Neurosci Res"},{"key":"1518_CR56","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","volume":"372","author":"C Holmes","year":"2008","unstructured":"Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Abeta42 immunisation in Alzheimer\u2019s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216\u2013223","journal-title":"Lancet"},{"key":"1518_CR57","first-page":"969","volume":"69","author":"LS Honig","year":"2012","unstructured":"Honig LS (2012) Translational research in neurology: dementia. Arch Neurol 69:969\u2013977","journal-title":"Arch Neurol"},{"key":"1518_CR58","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/1742-2094-8-171","volume":"8","author":"JJ Hoozemans","year":"2011","unstructured":"Hoozemans JJ, Rozemuller AJ, van Haastert ES, Eikelenboom P, van Gool WA (2011) Neuroinflammation in Alzheimer\u2019s disease wanes with age. J Neuroinflammation 8:171","journal-title":"J Neuroinflammation"},{"key":"1518_CR59","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1093\/brain\/awr268","volume":"134","author":"I Ifergan","year":"2011","unstructured":"Ifergan I, Kebir H, Alvarez JI, Marceau G, Bernard M, Bourbonniere L, Poirier J, Duquette P, Talbot PJ, Arbour N, Prat A (2011) Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on alpha4 integrin. Brain 134:3560\u20133577","journal-title":"Brain"},{"key":"1518_CR60","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ana.22519","volume":"70","author":"I Ifergan","year":"2011","unstructured":"Ifergan I, Kebir H, Terouz S, Alvarez JI, Lecuyer MA, Gendron S, Bourbonniere L, Dunay IR, Bouthillier A, Moumdjian R, Fontana A, Haqqani A, Klopstein A, Prinz M, Lopez-Vales R, Birchler T, Prat A (2011) Role of Ninjurin-1 in the migration of myeloid cells to central nervous system inflammatory lesions. Ann Neurol 70:751\u2013763","journal-title":"Ann Neurol"},{"key":"1518_CR61","first-page":"CD006378","volume":"2","author":"D Jaturapatporn","year":"2012","unstructured":"Jaturapatporn D, Isaac MG, McCleery J, Tabet N (2012) Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer\u2019s disease. Cochrane Database Syst Rev 2:CD006378","journal-title":"Cochrane Database Syst Rev"},{"key":"1518_CR62","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1084\/jem.20142322","volume":"212","author":"TR Jay","year":"2015","unstructured":"Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, Cotleur AC, Butovsky O, Bekris L, Staugaitis SM, Leverenz JB, Pimplikar SW, Landreth GE, Howell GR, Ransohoff RM, Lamb BT (2015) TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer\u2019s disease mouse models. J Exp Med 212:287\u2013295","journal-title":"J Exp Med"},{"key":"1518_CR63","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1038\/npp.2014.164","volume":"39","author":"T Jiang","year":"2014","unstructured":"Jiang T, Tan L, Zhu XC, Zhang QQ, Cao L, Tan MS, Gu LZ, Wang HF, Ding ZZ, Zhang YD, Yu JT (2014) Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer\u2019s disease. Neuropsychopharmacology 39:2949\u20132962","journal-title":"Neuropsychopharmacology"},{"key":"1518_CR64","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K (2013) Variant of TREM2 associated with the risk of Alzheimer\u2019s disease. N Engl J Med 368:107\u2013116","journal-title":"N Engl J Med"},{"key":"1518_CR65","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.neurobiolaging.2008.08.022","volume":"31","author":"C Julien","year":"2010","unstructured":"Julien C, Tremblay C, Phivilay A, Berthiaume L, Emond V, Julien P, Calon F (2010) High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiol Aging 31:1516\u20131531","journal-title":"Neurobiol Aging"},{"key":"1518_CR66","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jns.2012.07.032","volume":"322","author":"RN Kalaria","year":"2012","unstructured":"Kalaria RN, Akinyemi R, Ihara M (2012) Does vascular pathology contribute to Alzheimer changes? J Neurol Sci 322:141\u2013147","journal-title":"J Neurol Sci"},{"key":"1518_CR67","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1373\/clinchem.2013.202937","volume":"59","author":"JH Kang","year":"2013","unstructured":"Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM (2013) Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-beta(1\u201342) and tau proteins as Alzheimer disease biomarkers. Clin Chem 59:903\u2013916","journal-title":"Clin Chem"},{"key":"1518_CR68","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3389\/fimmu.2012.00357","volume":"3","author":"K Kedzierska","year":"2012","unstructured":"Kedzierska K, Valkenburg SA, Doherty PC, Davenport MP, Venturi V (2012) Use it or lose it: establishment and persistence of T cell memory. Front Immunol 3:357","journal-title":"Front Immunol"},{"key":"1518_CR69","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1084\/jem.20121274","volume":"209","author":"J Kim","year":"2012","unstructured":"Kim J, Eltorai AE, Jiang H, Liao F, Verghese PB, Kim J, Stewart FR, Basak JM, Holtzman DM (2012) Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis. J Exp Med 209:2149\u20132156","journal-title":"J Exp Med"},{"key":"1518_CR70","doi-asserted-by":"crossref","first-page":"8180","DOI":"10.1073\/pnas.0402268101","volume":"101","author":"J Kipnis","year":"2004","unstructured":"Kipnis J, Cohen H, Cardon M, Ziv Y, Schwartz M (2004) T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc Natl Acad Sci USA 101:8180\u20138185","journal-title":"Proc Natl Acad Sci USA"},{"key":"1518_CR71","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11910-015-0572-y","volume":"15","author":"HS Kirshner","year":"2015","unstructured":"Kirshner HS, Bradshaw M (2015) The inflammatory form of cerebral amyloid angiopathy or \u201ccerebral amyloid angiopathy-related inflammation\u201d (CAARI). Curr Neurol Neurosci Rep 15:54","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1518_CR72","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.neurobiolaging.2012.08.009","volume":"34","author":"T Kiyota","year":"2013","unstructured":"Kiyota T, Gendelman HE, Weir RA, Higgins EE, Zhang G, Jain M (2013) CCL2 affects beta-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer\u2019s disease. Neurobiol Aging 34:1060\u20131068","journal-title":"Neurobiol Aging"},{"key":"1518_CR73","doi-asserted-by":"crossref","first-page":"243ra86","DOI":"10.1126\/scitranslmed.3009093","volume":"6","author":"G Kleinberger","year":"2014","unstructured":"Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F, Tahirovic S, Lleo A, Alcolea D, Fortea J, Willem M, Lammich S, Molinuevo JL, Sanchez-Valle R, Antonell A, Ramirez A, Heneka MT, Sleegers K, van der Zee J, Martin JJ, Engelborghs S, Demirtas-Tatlidede A, Zetterberg H, Van Broeckhoven C, Gurvit H, Wyss-Coray T, Hardy J, Colonna M, Haass C (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6:243ra86","journal-title":"Sci Transl Med"},{"key":"1518_CR74","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fendo.2013.00076","volume":"4","author":"M Kornete","year":"2013","unstructured":"Kornete M, Mason ES, Piccirillo CA (2013) Immune regulation in T1D and T2D: prospective role of Foxp3+ Treg cells in disease pathogenesis and treatment. Front Endocrinol 4:76","journal-title":"Front Endocrinol"},{"key":"1518_CR75","doi-asserted-by":"crossref","first-page":"a006320","DOI":"10.1101\/cshperspect.a006320","volume":"2","author":"FM LaFerla","year":"2012","unstructured":"LaFerla FM, Green KN (2012) Animal models of Alzheimer disease. Cold Spring Harb Perspect Med 2:a006320","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1518_CR76","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/WNF.0b013e31827db49b","volume":"36","author":"JW Landen","year":"2013","unstructured":"Landen JW, Zhao Q, Cohen S, Borrie M, Woodward M, Billing CBJ, Bales K, Alvey C, McCush F, Yang J, Kupiec JW, Bednar MM (2013) Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study. Clin Neuropharmacol 36:14\u201323","journal-title":"Clin Neuropharmacol"},{"key":"1518_CR77","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3233\/JAD-2009-1015","volume":"17","author":"A Larbi","year":"2009","unstructured":"Larbi A, Pawelec G, Witkowski JM, Schipper HM, Derhovanessian E, Goldeck D, Fulop T (2009) Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer\u2019s disease. J Alzheimers Dis 17:91\u2013103","journal-title":"J Alzheimers Dis"},{"key":"1518_CR78","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3233\/NUA-150049","volume":"3","author":"S Lay\u00e9","year":"2015","unstructured":"Lay\u00e9 S, Madore C, St-Amour I, Delpech JC, Joffre C, Nadjar A, Calon F (2015) N-3 polyunsaturated fatty acid and neuroinflammation in aging and Alzheimer\u2019s disease. Nutr Aging 3:33\u201347","journal-title":"Nutr Aging"},{"key":"1518_CR79","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1074\/jbc.M511018200","volume":"281","author":"EB Lee","year":"2006","unstructured":"Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VM-Y (2006) Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 281:4292\u20134299","journal-title":"J Biol Chem"},{"key":"1518_CR80","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12272-013-0023-8","volume":"36","author":"J Lee","year":"2013","unstructured":"Lee J (2013) Adipose tissue macrophages in the development of obesity-induced inflammation, insulin resistance and type 2 diabetes. Arch Pharm Res 36:208\u2013222","journal-title":"Arch Pharm Res"},{"key":"1518_CR81","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1172\/JCI25410","volume":"116","author":"Y Levites","year":"2006","unstructured":"Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE (2006) Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest 116:193\u2013201","journal-title":"J Clin Invest"},{"key":"1518_CR82","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/alzrt249","volume":"6","author":"T Leyhe","year":"2014","unstructured":"Leyhe T, Andreasen N, Simeoni M, Reich A, von Arnim CA, Tong X, Yeo A, Khan S, Loercher A, Chalker M, Hottenstein C, Zetterberg H, Hilpert J, Mistry P (2014) Modulation of beta-amyloid by a single dose of GSK933776 in patients with mild Alzheimer\u2019s disease: a phase I study. Alzheimers Res Ther 6:19","journal-title":"Alzheimers Res Ther"},{"key":"1518_CR83","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s11481-011-9329-9","volume":"7","author":"Q Li","year":"2012","unstructured":"Li Q, Lebson L, Lee DC, Nash K, Grimm J, Rosenthal A, Selenica ML, Morgan D, Gordon MN (2012) Chronological age impacts immunotherapy and monocyte uptake independent of amyloid load. J Neuroimmune Pharmacol 7:202\u2013214","journal-title":"J Neuroimmune Pharmacol"},{"key":"1518_CR84","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0646-14.2014","volume":"34","author":"F Liao","year":"2014","unstructured":"Liao F, Hori Y, Hudry E, Bauer AQ, Jiang H, Mahan TE, Lefton KB, Zhang TJ, Dearborn JT, Kim J, Culver JP, Betensky R, Wozniak DF, Hyman BT, Holtzman DM (2014) Anti-ApoE antibody given after plaque onset decreases Abeta accumulation and improves brain function in a mouse model of Abeta amyloidosis. J Neurosci 34:7281\u20137292","journal-title":"J Neurosci"},{"key":"1518_CR85","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1523\/JNEUROSCI.5924-12.2013","volume":"33","author":"B Liu","year":"2013","unstructured":"Liu B, Frost JL, Sun J, Fu H, Grimes S, Blackburn P, Lemere CA (2013) MER5101, a novel Abeta1-15: DT conjugate vaccine, generates a robust anti-Abeta antibody response and attenuates Abeta pathology and cognitive deficits in APPswe\/PS1DeltaE9 transgenic mice. J Neurosci 33:7027\u20137037","journal-title":"J Neurosci"},{"key":"1518_CR86","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neurobiolaging.2008.03.024","volume":"31","author":"YJ Liu","year":"2010","unstructured":"Liu YJ, Guo DW, Tian L, Shang DS, Zhao WD, Li B, Fang WG, Zhu L, Chen YH (2010) Peripheral T cells derived from Alzheimer\u2019s disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-alpha-dependent. Neurobiol Aging 31:175\u2013188","journal-title":"Neurobiol Aging"},{"key":"1518_CR87","first-page":"628070","volume":"2012","author":"K Lobello","year":"2012","unstructured":"Lobello K, Ryan JM, Liu E, Rippon G, Black R (2012) Targeting beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer\u2019s disease. Int J Alzheimers Dis 2012:628070","journal-title":"Int J Alzheimers Dis"},{"key":"1518_CR88","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1742-2094-5-9","volume":"5","author":"DA Loeffler","year":"2008","unstructured":"Loeffler DA, Camp DM, Bennett DA (2008) Plaque complement activation and cognitive loss in Alzheimer\u2019s disease. J Neuroinflammation 5:9","journal-title":"J Neuroinflammation"},{"key":"1518_CR89","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.neurobiolaging.2003.11.003","volume":"25","author":"DA Loeffler","year":"2004","unstructured":"Loeffler DA, Camp DM, Schonberger MB, Singer DJ, LeWitt PA (2004) Early complement activation increases in the brain in some aged normal subjects. Neurobiol Aging 25:1001\u20131007","journal-title":"Neurobiol Aging"},{"key":"1518_CR90","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0165-5728(99)00046-6","volume":"97","author":"VR Lombardi","year":"1999","unstructured":"Lombardi VR, Garcia M, Rey L, Cacabelos R (1999) Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer\u2019s Disease (AD) individuals. J Neuroimmunol 97:163\u2013171","journal-title":"J Neuroimmunol"},{"key":"1518_CR91","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.neurobiolaging.2006.02.013","volume":"28","author":"S-M Man","year":"2007","unstructured":"Man S-M, Ma Y-R, Shang D-S, Zhao W-D, Li B, Guo D-W, Fang W-G, Zhu L, Chen Y-H (2007) Peripheral T cells overexpress MIP-1alpha to enhance its transendothelial migration in Alzheimer\u2019s disease. Neurobiol Aging 28:485\u2013496","journal-title":"Neurobiol Aging"},{"key":"1518_CR92","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/icb.2010.134","volume":"89","author":"F Mantile","year":"2011","unstructured":"Mantile F, Basile C, Cicatiello V, De Diana F, Caivano A, De Piergiuseppe B, Prisco A (2011) A multimeric immunogen for the induction of immune memory to beta-amyloid. Immunol Cell Biol 89:604\u2013609","journal-title":"Immunol Cell Biol"},{"key":"1518_CR93","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/archneur.2008.65.7.nct70006","volume":"65","author":"BK Martin","year":"2008","unstructured":"Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M (2008) Cognitive function over time in the Alzheimer\u2019s disease anti-inflammatory prevention trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65:896\u2013905","journal-title":"Arch Neurol"},{"key":"1518_CR94","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/01.WNL.0000148590.39911.DF","volume":"64","author":"E Masliah","year":"2005","unstructured":"Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64:129\u2013131","journal-title":"Neurology"},{"key":"1518_CR95","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00401-013-1177-7","volume":"126","author":"PL McGeer","year":"2013","unstructured":"McGeer PL, McGeer EG (2013) The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol 126:479\u2013497","journal-title":"Acta Neuropathol"},{"key":"1518_CR96","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.116.303697","volume":"116","author":"WG McMaster","year":"2015","unstructured":"McMaster WG, Kirabo A, Madhur MS, Harrison DG (2015) Inflammation, immunity, and hypertensive end-organ damage. Circ Res 116:1022\u20131033","journal-title":"Circ Res"},{"key":"1518_CR97","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jalz.2008.09.004","volume":"5","author":"CL Meinert","year":"2009","unstructured":"Meinert CL, McCaffrey LD, Breitner JC (2009) Alzheimer\u2019s disease anti-inflammatory prevention trial: design, methods, and baseline results. Alzheimers Dement 5:93\u2013104","journal-title":"Alzheimers Dement"},{"key":"1518_CR98","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/ncb1356","volume":"8","author":"J Millan","year":"2006","unstructured":"Millan J, Hewlett L, Glyn M, Toomre D, Clark P, Ridley AJ (2006) Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola- and F-actin-rich domains. Nat Cell Biol 8:113\u2013123","journal-title":"Nat Cell Biol"},{"key":"1518_CR99","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.exger.2004.07.007","volume":"39","author":"A Mocali","year":"2004","unstructured":"Mocali A, Cedrola S, Della Malva N, Bontempelli M, Mitidieri VA, Bavazzano A, Comolli R, Paoletti F, La Porta CA (2004) Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease. Exp Gerontol 39:1555\u20131561","journal-title":"Exp Gerontol"},{"key":"1518_CR100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1742-4933-10-18","volume":"10","author":"J Moreth","year":"2013","unstructured":"Moreth J, Mavoungou C, Schindowski K (2013) Passive anti-amyloid immunotherapy in Alzheimer\u2019s disease: What are the most promising targets? Immun Ageing 10:18","journal-title":"Immun Ageing"},{"key":"1518_CR101","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/jcbfm.2012.153","volume":"33","author":"LL Muldoon","year":"2013","unstructured":"Muldoon LL, Alvarez JI, Begley DJ, Boado RJ, Del Zoppo GJ, Doolittle ND, Engelhardt B, Hallenbeck JM, Lonser RR, Ohlfest JR, Prat A, Scarpa M, Smeyne RJ, Drewes LR, Neuwelt EA (2013) Immunologic privilege in the central nervous system and the blood\u2013brain barrier. J Cereb Blood Flow Metab 33:13\u201321","journal-title":"J Cereb Blood Flow Metab"},{"key":"1518_CR102","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1365-2222.2012.04014.x","volume":"42","author":"P Nair","year":"2012","unstructured":"Nair P, Gaga M, Zervas E, Alagha K, Hargreave FE, O\u2019Byrne PM, Stryszak P, Gann L, Sadeh J, Chanez P (2012) Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 42:1097\u20131103","journal-title":"Clin Exp Allergy"},{"key":"1518_CR103","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2174\/156720501108140910122849","volume":"11","author":"CM Nascimento","year":"2014","unstructured":"Nascimento CM, Pereira JR, de Andrade LP, Garuffi M, Talib LL, Forlenza OV, Cancela JM, Cominetti MR, Stella F (2014) Physical exercise in MCI elderly promotes reduction of pro-inflammatory cytokines and improvements on cognition and BDNF peripheral levels. Curr Alzheimer Res 11:799\u2013805","journal-title":"Curr Alzheimer Res"},{"key":"1518_CR104","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","volume":"9","author":"JA Nicoll","year":"2003","unstructured":"Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9:448\u2013452","journal-title":"Nat Med"},{"key":"1518_CR105","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/scd.2008.0018","volume":"17","author":"WV Nikolic","year":"2008","unstructured":"Nikolic WV, Hou H, Town T, Zhu Y, Giunta B, Sanberg CD, Zeng J, Luo D, Ehrhart J, Mori T, Sanberg PR, Tan J (2008) Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice. Stem Cells Dev 17:423\u2013439","journal-title":"Stem Cells Dev"},{"key":"1518_CR106","doi-asserted-by":"crossref","first-page":"39413","DOI":"10.1074\/jbc.M608485200","volume":"281","author":"S Oddo","year":"2006","unstructured":"Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM (2006) Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 281:39413\u201339423","journal-title":"J Biol Chem"},{"key":"1518_CR107","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46\u201354","journal-title":"Neurology"},{"key":"1518_CR108","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","volume":"69","author":"S Ostrowitzki","year":"2012","unstructured":"Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, Loetscher H, Santarelli L (2012) Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69:198\u2013207","journal-title":"Arch Neurol"},{"key":"1518_CR109","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/glia.22892","volume":"63","author":"B Parajuli","year":"2015","unstructured":"Parajuli B, Horiuchi H, Mizuno T, Takeuchi H, Suzumura A (2015) CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia. Glia 63:2274\u20132284","journal-title":"Glia"},{"key":"1518_CR110","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jalz.2009.06.003","volume":"5","author":"WM Pardridge","year":"2009","unstructured":"Pardridge WM (2009) Alzheimer\u2019s disease drug development and the problem of the blood\u2013brain barrier. Alzheimers Dement 5:427\u2013432","journal-title":"Alzheimers Dement"},{"key":"1518_CR111","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0306-4522(98)00218-8","volume":"87","author":"GM Pasinetti","year":"1998","unstructured":"Pasinetti GM, Aisen PS (1998) Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer\u2019s disease brain. Neuroscience 87:319\u2013324","journal-title":"Neuroscience"},{"key":"1518_CR112","first-page":"19","volume":"24","author":"KR Patel","year":"2015","unstructured":"Patel KR (2015) Biogen\u2019s aducanumab raises hope that Alzheimer\u2019s can be treated at its source. Manag Care 24:19","journal-title":"Manag Care"},{"key":"1518_CR113","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jneuroim.2011.11.005","volume":"242","author":"M Pellicano","year":"2012","unstructured":"Pellicano M, Larbi A, Goldeck D, Colonna-Romano G, Buffa S, Bulati M, Rubino G, Iemolo F, Candore G, Caruso C, Derhovanessian E, Pawelec G (2012) Immune profiling of Alzheimer patients. J Neuroimmunol 242:52\u201359","journal-title":"J Neuroimmunol"},{"key":"1518_CR114","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1742-2094-5-42","volume":"5","author":"I Petrushina","year":"2008","unstructured":"Petrushina I, Ghochikyan A, Mkrtichyan M, Mamikonyan G, Movsesyan N, Ajdari R, Vasilevko V, Karapetyan A, Lees A, Agadjanyan MG, Cribbs DH (2008) Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. J Neuroinflammation 5:42","journal-title":"J Neuroinflammation"},{"key":"1518_CR115","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0022-510X(92)90284-R","volume":"107","author":"T Pirttila","year":"1992","unstructured":"Pirttila T, Mattinen S, Frey H (1992) The decrease of CD8-positive lymphocytes in Alzheimer\u2019s disease. J Neurol Sci 107:160\u2013165","journal-title":"J Neurol Sci"},{"key":"1518_CR116","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00401-013-1182-x","volume":"126","author":"S Prokop","year":"2013","unstructured":"Prokop S, Miller KR, Heppner FL (2013) Microglia actions in Alzheimer\u2019s disease. Acta Neuropathol 126:461\u2013477","journal-title":"Acta Neuropathol"},{"key":"1518_CR117","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1742-2094-9-105","volume":"9","author":"L Puli","year":"2012","unstructured":"Puli L, Pomeshchik Y, Olas K, Malm T, Koistinaho J, Tanila H (2012) Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer\u2019s disease. J Neuroinflammation 9:105","journal-title":"J Neuroinflammation"},{"key":"1518_CR118","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jneuroim.2003.11.003","volume":"148","author":"M Reale","year":"2004","unstructured":"Reale M, Iarlori C, Gambi F, Feliciani C, Salone A, Toma L, DeLuca G, Salvatore M, Conti P, Gambi D (2004) Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J Neuroimmunol 148:162\u2013171","journal-title":"J Neuroimmunol"},{"issue":"Suppl 1","key":"1518_CR119","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1007\/s10875-014-0041-4","volume":"34","author":"N Relkin","year":"2014","unstructured":"Relkin N (2014) Clinical trials of intravenous immunoglobulin for Alzheimer\u2019s disease. J Clin Immunol 34(Suppl 1):S74\u2013S79","journal-title":"J Clin Immunol"},{"key":"1518_CR120","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/rccm.201405-0992OC","volume":"191","author":"SI Rennard","year":"2015","unstructured":"Rennard SI, Dale DC, Donohue JF, Kanniess F, Magnussen H, Sutherland ER, Watz H, Lu S, Stryszak P, Rosenberg E, Staudinger H (2015) CXCR2 antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 191:1001\u20131011","journal-title":"Am J Respir Crit Care Med"},{"key":"1518_CR121","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1586\/ern.09.118","volume":"9","author":"K Rezai-Zadeh","year":"2009","unstructured":"Rezai-Zadeh K, Gate D, Szekely CA, Town T (2009) Can peripheral leukocytes be used as Alzheimer\u2019s disease biomarkers? Expert Rev Neurother 9:1623\u20131633","journal-title":"Expert Rev Neurother"},{"key":"1518_CR122","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","volume":"31","author":"E Ricciotti","year":"2011","unstructured":"Ricciotti E, FitzGerald GA (2011) Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 31:986\u20131000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1518_CR123","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jpsychires.2004.12.005","volume":"39","author":"E Richartz","year":"2005","unstructured":"Richartz E, Stransky E, Batra A, Simon P, Lewczuk P, Buchkremer G, Bartels M, Schott K (2005) Decline of immune responsiveness: A pathogenetic factor in Alzheimer\u2019s disease? J Psychiatr Res 39:535\u2013543","journal-title":"J Psychiatr Res"},{"key":"1518_CR124","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.4049\/jimmunol.1203200","volume":"190","author":"D Ricklin","year":"2013","unstructured":"Ricklin D, Lambris JD (2013) Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol 190:3839\u20133847","journal-title":"J Immunol"},{"key":"1518_CR125","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.neurobiolaging.2003.12.020","volume":"25","author":"SR Robinson","year":"2004","unstructured":"Robinson SR, Bishop GM, Lee H-G, Munch G (2004) Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol Aging 25:609\u2013615","journal-title":"Neurobiol Aging"},{"key":"1518_CR126","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1017\/S0029665110001795","volume":"69","author":"J Romeo","year":"2010","unstructured":"Romeo J, Warnberg J, Pozo T, Marcos A (2010) Physical activity, immunity and infection. Proc Nutr Soc 69:390\u2013399","journal-title":"Proc Nutr Soc"},{"key":"1518_CR127","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1001\/archneur.63.10.1459","volume":"63","author":"H Rosenmann","year":"2006","unstructured":"Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, Abramsky O (2006) Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 63:1459\u20131467","journal-title":"Arch Neurol"},{"issue":"Suppl","key":"1518_CR128","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1194\/jlr.R800042-JLR200","volume":"50","author":"CA Rouzer","year":"2009","unstructured":"Rouzer CA, Marnett LJ (2009) Cyclooxygenases: structural and functional insights. J Lipid Res 50(Suppl):S29\u2013S34","journal-title":"J Lipid Res"},{"key":"1518_CR129","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1385\/IR:33:2:103","volume":"33","author":"H Rus","year":"2005","unstructured":"Rus H, Cudrici C, Niculescu F (2005) The role of the complement system in innate immunity. Immunol Res 33:103\u2013112","journal-title":"Immunol Res"},{"key":"1518_CR130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s12026-012-8289-3","volume":"53","author":"PD Rymkiewicz","year":"2012","unstructured":"Rymkiewicz PD, Heng YX, Vasudev A, Larbi A (2012) The immune system in the aging human. Immunol Res 53:235\u2013250","journal-title":"Immunol Res"},{"key":"1518_CR131","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 370:322\u2013333","journal-title":"N Engl J Med"},{"key":"1518_CR132","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bbi.2010.12.004","volume":"25","author":"M Saresella","year":"2011","unstructured":"Saresella M, Calabrese E, Marventano I, Piancone F, Gatti A, Alberoni M, Nemni R, Clerici M (2011) Increased activity of Th-17 and Th-9 lymphocytes and a skewing of the post-thymic differentiation pathway are seen in Alzheimer\u2019s disease. Brain Behav Immun 25:539\u2013547","journal-title":"Brain Behav Immun"},{"key":"1518_CR133","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1212\/WNL.43.8.1467","volume":"43","author":"AM Saunders","year":"1993","unstructured":"Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ et al (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer\u2019s disease. Neurology 43:1467\u20131472","journal-title":"Neurology"},{"key":"1518_CR134","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00401-012-0996-2","volume":"124","author":"GD Schellenberg","year":"2012","unstructured":"Schellenberg GD, Montine TJ (2012) The genetics and neuropathology of Alzheimer\u2019s disease. Acta Neuropathol 124:305\u2013323","journal-title":"Acta Neuropathol"},{"key":"1518_CR135","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173\u2013177","journal-title":"Nature"},{"key":"1518_CR136","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/ana.24001","volume":"74","author":"DJ Selkoe","year":"2013","unstructured":"Selkoe DJ (2013) The therapeutics of Alzheimer\u2019s disease: where we stand and where we are heading. Ann Neurol 74:328\u2013336","journal-title":"Ann Neurol"},{"key":"1518_CR137","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2147\/ciia.2007.2.1.3","volume":"2","author":"DS Senchina","year":"2007","unstructured":"Senchina DS, Kohut ML (2007) Immunological outcomes of exercise in older adults. Clin Interv Aging 2:3\u201316","journal-title":"Clin Interv Aging"},{"key":"1518_CR138","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0006-8993(97)00850-0","volume":"769","author":"Y Shen","year":"1997","unstructured":"Shen Y, Li R, McGeer EG, McGeer PL (1997) Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res 769:391\u2013395","journal-title":"Brain Res"},{"key":"1518_CR139","author":"ER Siemers","year":"2015","unstructured":"Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, Dowsett SA, Pontecorvo MJ, Dean RA, Demattos R (2015) Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer\u2019s disease patients. Alzheimers Dement. doi: 10.1016\/j.jalz.2015.06.1893","journal-title":"Alzheimers Dement"},{"key":"1518_CR140","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1750-3639.2008.00188.x","volume":"19","author":"A Sokolova","year":"2009","unstructured":"Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE (2009) Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer\u2019s disease. Brain Pathol 19:392\u2013398","journal-title":"Brain Pathol"},{"key":"1518_CR141","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.neurobiolaging.2006.05.020","volume":"28","author":"L Speciale","year":"2007","unstructured":"Speciale L, Calabrese E, Saresella M, Tinelli C, Mariani C, Sanvito L, Longhi R, Ferrante P (2007) Lymphocyte subset patterns and cytokine production in Alzheimer\u2019s disease patients. Neurobiol Aging 28:1163\u20131169","journal-title":"Neurobiol Aging"},{"key":"1518_CR142","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","volume":"84","author":"R Sperling","year":"2014","unstructured":"Sperling R, Mormino E, Johnson K (2014) The evolution of preclinical Alzheimer\u2019s disease: implications for prevention trials. Neuron 84:608\u2013622","journal-title":"Neuron"},{"key":"1518_CR143","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","volume":"11","author":"R Sperling","year":"2012","unstructured":"Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M (2012) Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 11:241\u2013249","journal-title":"Lancet Neurol"},{"key":"1518_CR144","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/jcbfm.2013.160","volume":"33","author":"I St-Amour","year":"2013","unstructured":"St-Amour I, Pare I, Alata W, Coulombe K, Ringuette-Goulet C, Drouin-Ouellet J, Vandal M, Soulet D, Bazin R, Calon F (2013) Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood\u2013brain barrier. J Cereb Blood Flow Metab 33:1983\u20131992","journal-title":"J Cereb Blood Flow Metab"},{"key":"1518_CR145","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1742-2094-11-54","volume":"11","author":"I St-Amour","year":"2014","unstructured":"St-Amour I, Pare I, Tremblay C, Coulombe K, Bazin R, Calon F (2014) IVIg protects the 3xTg-AD mouse model of Alzheimer\u2019s disease from memory deficit and Abeta pathology. J Neuroinflammation 11:54","journal-title":"J Neuroinflammation"},{"key":"1518_CR146","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1097\/00001756-200112210-00023","volume":"12","author":"JT Stieler","year":"2001","unstructured":"Stieler JT, Lederer C, Bruckner MK, Wolf H, Holzer M, Gertz HJ, Arendt T (2001) Impairment of mitogenic activation of peripheral blood lymphocytes in Alzheimer\u2019s disease. NeuroReport 12:3969\u20133972","journal-title":"NeuroReport"},{"key":"1518_CR147","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","volume":"90","author":"WJ Strittmatter","year":"1993","unstructured":"Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90:1977\u20131981","journal-title":"Proc Natl Acad Sci USA"},{"key":"1518_CR148","doi-asserted-by":"crossref","first-page":"9684","DOI":"10.1523\/JNEUROSCI.1220-13.2013","volume":"33","author":"TL Sudduth","year":"2013","unstructured":"Sudduth TL, Greenstein A, Wilcock DM (2013) Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Abeta in APP\/PS1 mice along a different time course than anti-Abeta antibodies. J Neurosci 33:9684\u20139692","journal-title":"J Neurosci"},{"key":"1518_CR149","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.autrev.2008.03.007","volume":"7","author":"P Szabo","year":"2008","unstructured":"Szabo P, Relkin N, Weksler ME (2008) Natural human antibodies to amyloid beta peptide. Autoimmun Rev 7:415\u2013420","journal-title":"Autoimmun Rev"},{"key":"1518_CR150","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1189\/jlb.0608385","volume":"85","author":"BR Tambuyzer","year":"2009","unstructured":"Tambuyzer BR, Ponsaerts P, Nouwen EJ (2009) Microglia: gatekeepers of central nervous system immunology. J Leukoc Biol 85:352\u2013370","journal-title":"J Leukoc Biol"},{"key":"1518_CR151","doi-asserted-by":"crossref","first-page":"a006296","DOI":"10.1101\/cshperspect.a006296","volume":"2","author":"RE Tanzi","year":"2012","unstructured":"Tanzi RE (2012) The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2:a006296","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1518_CR152","doi-asserted-by":"crossref","first-page":"a006148","DOI":"10.1101\/cshperspect.a006148","volume":"2","author":"R Tarawneh","year":"2012","unstructured":"Tarawneh R, Holtzman DM (2012) The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb Perspect Med 2:a006148","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1518_CR153","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000355555","volume":"37","author":"E Teng","year":"2014","unstructured":"Teng E, Yamasaki TR, Tran M, Hsiao JJ, Sultzer DL, Mendez MF (2014) Cerebrospinal fluid biomarkers in clinical subtypes of early-onset Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 37:307\u2013314","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1518_CR154","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrn2977","volume":"12","author":"A Thathiah","year":"2011","unstructured":"Thathiah A, De Strooper B (2011) The role of G protein-coupled receptors in the pathology of Alzheimer\u2019s disease. Nat Rev Neurosci 12:73\u201387","journal-title":"Nat Rev Neurosci"},{"key":"1518_CR155","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0006-8993(00)02984-X","volume":"885","author":"T Togo","year":"2000","unstructured":"Togo T, Akiyama H, Kondo H, Ikeda K, Kato M, Iseki E, Kosaka K (2000) Expression of CD40 in the brain of Alzheimer\u2019s disease and other neurological diseases. Brain Res 885:117\u2013121","journal-title":"Brain Res"},{"key":"1518_CR156","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3233\/JAD-2007-12411","volume":"12","author":"C Tremblay","year":"2007","unstructured":"Tremblay C, Pilote M, Phivilay A, Emond V, Bennett DA, Calon F (2007) Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer\u2019s disease. J Alzheimers Dis 12:377\u2013390","journal-title":"J Alzheimers Dis"},{"key":"1518_CR157","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1096\/fj.14-268482","volume":"29","author":"M Vandal","year":"2015","unstructured":"Vandal M, White PJ, Chevrier G, Tremblay C, St-Amour I, Planel E, Marette A, Calon F (2015) Age-dependent impairment of glucose tolerance in the 3xTg-AD mouse model of Alzheimer\u2019s disease. FASEB J 29:4273\u20134284","journal-title":"FASEB J"},{"key":"1518_CR158","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.2337\/db14-0375","volume":"63","author":"M Vandal","year":"2014","unstructured":"Vandal M, White PJ, Tremblay C, St-Amour I, Chevrier G, Emond V, Lefrancois D, Virgili J, Planel E, Giguere Y, Marette A, Calon F (2014) Insulin reverses the high-fat diet-induced increase in brain Abeta and improves memory in an animal model of Alzheimer disease. Diabetes 63:4291\u20134301","journal-title":"Diabetes"},{"key":"1518_CR159","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature10357","volume":"477","author":"SA Villeda","year":"2011","unstructured":"Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, Fainberg N, Ding Z, Eggel A, Lucin KM, Czirr E, Park JS, Couillard-Despres S, Aigner L, Li G, Peskind ER, Kaye JA, Quinn JF, Galasko DR, Xie XS, Rando TA, Wyss-Coray T (2011) The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477:90\u201394","journal-title":"Nature"},{"key":"1518_CR160","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1212\/01.wnl.0000311269.57716.63","volume":"70","author":"SC Vlad","year":"2008","unstructured":"Vlad SC, Miller DR, Kowall NW, Felson DT (2008) Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70:1672\u20131677","journal-title":"Neurology"},{"key":"1518_CR161","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.nbd.2008.12.007","volume":"34","author":"V Vukic","year":"2009","unstructured":"Vukic V, Callaghan D, Walker D, Lue LF, Liu QY, Couraud PO, Romero IA, Weksler B, Stanimirovic DB, Zhang W (2009) Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer\u2019s brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis 34:95\u2013106","journal-title":"Neurobiol Dis"},{"key":"1518_CR162","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.expneurol.2008.09.003","volume":"215","author":"DG Walker","year":"2009","unstructured":"Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue LF (2009) Decreased expression of CD200 and CD200 receptor in Alzheimer\u2019s disease: a potential mechanism leading to chronic inflammation. Exp Neurol 215:5\u201319","journal-title":"Exp Neurol"},{"key":"1518_CR163","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","volume":"160","author":"Y Wang","year":"2015","unstructured":"Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, Holtzman DM, Cirrito JR, Colonna M (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer\u2019s disease model. Cell 160:1061\u20131071","journal-title":"Cell"},{"key":"1518_CR164","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1432-2277.2009.00927.x","volume":"22","author":"D Weiskopf","year":"2009","unstructured":"Weiskopf D, Weinberger B, Grubeck-Loebenstein B (2009) The aging of the immune system. Transpl Int 22:1041\u20131050","journal-title":"Transpl Int"},{"key":"1518_CR165","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cct.2014.04.001","volume":"38","author":"AL Whitehead","year":"2014","unstructured":"Whitehead AL, Sully BG, Campbell MJ (2014) Pilot and feasibility studies: Is there a difference from each other and from a randomised controlled trial? Contemp Clin Trials 38:130\u2013133","journal-title":"Contemp Clin Trials"},{"key":"1518_CR166","author":"D Wilcock","year":"2004","unstructured":"Wilcock D, Rojiani A, Rosenthal A, Subbarao S, Freeman M, Gordon M, Morgan D (2004) Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. doi: 10.1186\/1742-2094-1-24","journal-title":"J Neuroinflammation"},{"key":"1518_CR167","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.neuroscience.2006.10.020","volume":"144","author":"DM Wilcock","year":"2007","unstructured":"Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN (2007) Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 144:950\u2013960","journal-title":"Neuroscience"},{"key":"1518_CR168","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1523\/JNEUROSCI.1090-04.2004","volume":"24","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D (2004) Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24:6144\u20136151","journal-title":"J Neurosci"},{"key":"1518_CR169","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","volume":"11","author":"B Winblad","year":"2012","unstructured":"Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A (2012) Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer\u2019s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11:597\u2013604","journal-title":"Lancet Neurol"},{"key":"1518_CR170","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00401-004-0928-x","volume":"109","author":"H Wolburg","year":"2005","unstructured":"Wolburg H, Wolburg-Buchholz K, Engelhardt B (2005) Diapedesis of mononuclear cells across cerebral venules during experimental autoimmune encephalomyelitis leaves tight junctions intact. Acta Neuropathol 109:181\u2013190","journal-title":"Acta Neuropathol"},{"key":"1518_CR171","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.4049\/jimmunol.0801218","volume":"182","author":"SA Wolf","year":"2009","unstructured":"Wolf SA, Steiner B, Akpinarli A, Kammertoens T, Nassenstein C, Braun A, Blankenstein T, Kempermann G (2009) CD4-positive T lymphocytes provide a neuroimmunological link in the control of adult hippocampal neurogenesis. J Immunol 182:3979\u20133984","journal-title":"J Immunol"},{"key":"1518_CR172","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12974-015-0316-6","volume":"12","author":"F Wu","year":"2015","unstructured":"Wu F, Zhao Y, Jiao T, Shi D, Zhu X, Zhang M, Shi M, Zhou H (2015) CXCR2 is essential for cerebral endothelial activation and leukocyte recruitment during neuroinflammation. J Neuroinflammation 12:98","journal-title":"J Neuroinflammation"},{"key":"1518_CR173","doi-asserted-by":"crossref","first-page":"a006346","DOI":"10.1101\/cshperspect.a006346","volume":"2","author":"T Wyss-Coray","year":"2012","unstructured":"Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2:a006346","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1518_CR174","first-page":"1469","volume":"122","author":"SR Xue","year":"2009","unstructured":"Xue SR, Xu DH, Yang XX, Dong WL (2009) Alterations in lymphocyte subset patterns and co-stimulatory molecules in patients with Alzheimer disease. Chin Med J 122:1469\u20131472","journal-title":"Chin Med J"},{"key":"1518_CR175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.molmed.2009.12.001","volume":"16","author":"V Yanamadala","year":"2010","unstructured":"Yanamadala V, Friedlander RM (2010) Complement in neuroprotection and neurodegeneration. Trends Mol Med 16:69\u201376","journal-title":"Trends Mol Med"},{"key":"1518_CR176","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s11064-013-1138-5","volume":"38","author":"YM Yang","year":"2013","unstructured":"Yang YM, Shang DS, Zhao WD, Fang WG, Chen YH (2013) Microglial TNF-alpha-dependent elevation of MHC class I expression on brain endothelium induced by amyloid-beta promotes T cell transendothelial migration. Neurochem Res 38:2295\u20132304","journal-title":"Neurochem Res"},{"key":"1518_CR177","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1161\/HYPERTENSIONAHA.113.00689","volume":"62","author":"JC Youn","year":"2013","unstructured":"Youn JC, Yu HT, Lim BJ, Koh MJ, Lee J, Chang DY, Choi YS, Lee SH, Kang SM, Jang Y, Yoo OJ, Shin EC, Park S (2013) Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension 62:126\u2013133","journal-title":"Hypertension"},{"key":"1518_CR178","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/01.wad.0000165506.60370.94","volume":"19","author":"H Zanjani","year":"2005","unstructured":"Zanjani H, Finch CE, Kemper C, Atkinson J, McKeel D, Morris JC, Price JL (2005) Complement activation in very early Alzheimer disease. Alzheimer Dis Assoc Disord 19:55\u201366","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1518_CR179","doi-asserted-by":"crossref","first-page":"e72744","DOI":"10.1371\/journal.pone.0072744","volume":"8","author":"K Zhang","year":"2013","unstructured":"Zhang K, Tian L, Liu L, Feng Y, Dong YB, Li B, Shang DS, Fang WG, Cao YP, Chen YH (2013) CXCL1 contributes to beta-amyloid-induced transendothelial migration of monocytes in Alzheimer\u2019s disease. PLoS ONE 8:e72744","journal-title":"PLoS ONE"},{"key":"1518_CR180","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nrn3114","volume":"12","author":"BV Zlokovic","year":"2011","unstructured":"Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders. Nat Rev Neurosci 12:723\u2013738","journal-title":"Nat Rev Neurosci"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-015-1518-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00401-015-1518-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-015-1518-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T15:42:42Z","timestamp":1567438962000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00401-015-1518-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,21]]},"references-count":180,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["1518"],"URL":"https:\/\/doi.org\/10.1007\/s00401-015-1518-9","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,21]]}}}